GlassScriptPhysician profile
Charles Morales
NPI 1073519161
$4,636.10
in general payments reported to CMS, 2019-2025
25 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $890 · 2023: $1,036 · 2024: $1,422 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,584 · Education: $96.81 · Consulting Fee: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,583.97 |
| Education | $96.81 |
| Consulting Fee | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $802.15 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $764.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $582.39 | 2022-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $554.66 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $297.91 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.06 | 2022-2025 | Jardiance |
| Insulet Corporation | $277.00 | 2022-2025 | Omnipod, Omnipod |
| Mannkind Corporation | $212.82 | 2022-2023 | Afrezza |
| Medtronic, INC. | $186.39 | 2022-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $138.73 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $96.06 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $51.97 | 2022-2023 | |
| Radius Health, INC. | $50.44 | 2024 | |
| Esperion Therapeutics, INC. | $47.54 | 2023 | Nexletol |
| Halozyme INC | $44.19 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $31.52 | 2023 | Tepezza |
| Madrigal Pharmaceuticals | $31.14 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $30.11 | 2025 | Shingrix |
| Sandoz INC. | $28.23 | 2025 | Jubbonti |
| Becton, Dickinson and Company | $22.61 | 2022 | |
| Bigfoot Biomedical INC | $21.63 | 2022 | |
| Cequr Corporation | $20.34 | 2023 | Cequr Simplicity |
| Sequel Med Tech, LLC | $20.16 | 2025 | Twiist |
| Kyowa Kirin, INC. | $18.93 | 2024 | Crysvita |
| Antares Pharma, INC. | $15.14 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.